For the first time in many years, Nigeria’s pharmaceutical sector is enjoying an overdue moment of ascendance. The exit of multinational drug firms, once seen as a dangerous red flag for the country’s healthcare system, is proving to be the catalyst for a long-awaited realignment. One in which Nigerian manufacturers are no longer fighting for space but taking their rightful place at the centre of drug production and supply.
The latest earnings of listed pharmaceutical companies confirm what many industry watchers have suspected throughout 2024 and 2025: the vacuum created by multinational departures has become a launchpad for domestic dominance. Fidson Healthcare, MeCure Industries and May & Baker collectively posted N15.77 billion in profit in the first nine months of 2025, a staggering 127 percent jump from the same period last year. Beyond the impressive figures lies a more profound development – this is what an economy looks like when its local industries are given room to breathe.
“The present gains, although extraordinary, should be seen as the beginning of a transition and not the conclusion of one. Demand will continue to drive revenue, though analysts expect growth to moderate from the rapid acceleration seen in 2025.”
For decades, multinational companies defined Nigeria’s pharmaceutical landscape and shaped market standards. But their dominance came at a cost: local producers could not scale, hospital procurement favoured foreign brands, and foreign exchange-driven import dependency crippled price stability. The departure of companies like GSK in 2023 and Sanofi-Aventis in 2024, triggered in part by currency volatility and the difficulty of operating in a post-subsidy Nigeria, accelerated what had long been inevitable – local drugmakers had to step up or risk a total supply breakdown.
The beneficiaries are not just the manufacturers but the entire healthcare value chain. A growing population and rising illness burden have kept demand for medicines high. The weaker naira significantly raised the cost of imported drugs, redirecting both hospitals and consumers to locally produced alternatives. Medical tourism, once a threat to local viability, has slowed under economic pressure, indirectly expanding local access and improving consumer trust.
This shift is most stark in acute care products, pain medications and anti-infectives, areas where patient needs are urgent and non-negotiable. MeCure’s financials tell the story plainly – the full N60 billion it generated in revenue came from Nigeria, with N33.6 billion driven purely by acute treatments. Local production has become not merely an alternative, but the default.
Read also: Local drug makers fill multinationals’ void to boost profit to 5-yr high
To interpret this boom as a windfall driven only by currency instability is to miss the wider picture. Analysts observing market behaviour rightly note that the surge is structural, not cyclical. In both public and private hospitals, procurement of local drugs is rising in proportion to patient volumes. Retail pharmacies are expanding to meet demand from rapidly urbanising cities. Health management organisations (HMOs) are formalising steady purchasing channels that guarantee recurrent revenue. Even outside the formal sector, digital pharmacies are creating a new class of health-conscious, self-paying consumers.
The numbers reinforce this reality. Fidson recorded N93.1 billion in turnover, up from N59.7 billion last year, and profit more than doubled to N7.97 billion. MeCure grew 181 percent in profit on the back of contract manufacturing and higher facility utilisation. May & Baker delivered revenue gains of 35 per cent and profit growth of 74 percent. What is emerging is not accidental prosperity but evidence of operational discipline, investment in scale, and a largely untapped market coming to life.
This is how a pharmaceutical market should evolve: import substitution leading to domestic mastery, market space enabling innovation rather than suffocating it, and rising health demand translating into local industrial expansion rather than foreign profit extraction.
Still, capturing the moment is not the same as consolidating it.
For Nigeria to transition from local dominance to global competitiveness, regulation must become a pillar rather than a bottleneck. NAFDAC and the Pharmacists Council of Nigeria carry the responsibility of aligning Nigerian drug standards with global benchmarks, including WHO prequalification and full adherence to Good Manufacturing Practice protocols. Strengthening post-market surveillance and enforcing quality audits will protect consumers and prevent the industry from repeating the mistakes of other sectors where temporary advantages dissolved into complacency.
If the Nigerian pharmaceutical sector must succeed long-term, three imperatives stand out:
Industrial scale must deepen. Local producers require financing structures, beyond expensive commercial bank loans, to expand capacity, automate production, and boost research and development capabilities.
Export ambition must replace survival-mode thinking. The African Continental Free Trade Area (AfCFTA) presents a historic opportunity for Nigeria to become a regional pharmaceutical hub.
Read also: Drug makers’ input costs almost double amid weak naira
The value chain must be localised end-to-end. From active pharmaceutical ingredients (APIs) to packaging, the less the sector depends on imports, the more it can control cost, affordability and supply stability.
The present gains, although extraordinary, should be seen as the beginning of a transition and not the conclusion of one. Demand will continue to drive revenue, though analysts expect growth to moderate from the rapid acceleration seen in 2025. The real test will come when the economy stabilises, import pressure normalises and the multinational comeback narrative resurfaces. By then, Nigeria must have built a pharmaceutical sector too competitive to be overshadowed.
The exit of multinationals did not destroy the industry; it exposed how much it had been held back. Local drug manufacturers have demonstrated capacity, resilience and strategic agility. Now, Nigeria must do what successful economies do with emerging champions: protect them, regulate them to world-class standards, and position them as continental leaders.
If Nigeria sustains this trajectory, the lesson of 2025 will be clear – the nation does not need to wait for multinationals to make its healthcare system strong.
